Recruiting

A Novel Blood Test as a Biomarker in Mental Health

ClinicalTrials.gov IDNCT06856161

PhaseNot Applicable

Enrollment500

SponsorFraser Health

Age19 Years

SexALL

I'm interested View official listing

Conditions studied

Depression - Major Depressive Disorder, Schizophenia Disorder, Psychosis, Mania (Neurotic), Alcohol Consumption, Anxiety Disorder (Panic Disorder or GAD), Substance Use Disorders, Alcohol Use Disorder

About this study

This longitudinal, observational study aims to assess whether the characteristics of a novel blood peripheral biomarker can serve as indicators for depression and schizophrenia in patients at the Royal Columbian Hospital Psychiatric Clinics. The study will evaluate whether changes in these biomarker characteristics can help distinguish between depressed patients who do or do not respond to treatment and between individuals experiencing a single psychotic episode and those at risk of progressing to schizophrenia. To achieve this, blood samples and standardized mental health assessments will be collected across three study visits from up to 500 participants, grouped into two study arms based on their diagnosis: Depression (DEP) or Psychosis/Schizophrenia (PSY).

Primary outcomes

Relationship between Depression and Biomarker Characteristics (6 months from enrollment, across three study visits.)
Relationship between Psychotic Disorders and Biomarker Characteristics (6 months from enrollment, across 3 study visits.)

Eligibility information

Inclusion Criteria: I. Age 19+. II. Informed consent by participant III. Any of the following situations: 1. Suspected, new onset or established depression. 2. First episode of psychosis or suspected/established schizophrenia. IV. In the opinion of the Investigator, the participant will likely be able to complete the standardized mental health questionnaires administered in each study visit. Exclusion Criteria: I. Inability to provide informed consent. II. Currently enrolled in any other research study involving drugs or devices that may confound mental health treatment outcomes. III. Currently declared on extended leave Under British Columbia's Mental Health Act.

Study locations

Royal Columbian Hospital, New Westminster, British Columbia V3L 3M2 Canada

Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.

Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-09-27.